REM1
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
08/04/2025
Back to search
Official data from USPTO
M
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
64
Latest update
08/05/2025
Trademark type
Combined
Nice classes
5, 40, 42
Filing date
02/19/2016
Registration date
08/04/2020
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
08/04/2020
Last transaction
08/05/2025
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Filing basis
Intent to use, Foreign priority
Drawing code
5
Owner type
03
Owner location
Quebec (Quebec), CA
Examiner
SHINER,MARK W
Law office
L50
Current location
PUBLICATION AND ISSUE SECTION
Mark description
The mark consists of the letter "M" in stylized font.
Holders and representatives
Holders
MEDICAGO INC.
Representatives
Michelle P. Ciotola CANTOR COLBURN LLP
Technical classification
Nice Classes
Class 5Class 40Class 42
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Pharmaceutical and medicinal preparations and substanceshuman vaccinestherapeutic proteins and antibodies for treatment of infectious diseaseschronic diseases and cancer
Class 40
Manufacture of pharmaceuticalspharmaceutical ingredientsvaccines and antibodies for others
Class 42
Research and development in the field of vaccinesrecombinant proteins and antibodies for therapeutic and prophylactic use; high throughput vaccine engineering services; medical and scientific research services of proprietary recombinant protein platform technologies designed to lead to new human vaccinestherapeutic proteins and antibodies; product research and development and scientific research in the field of protein production using recombinant technologies through transient expression in plants; medical and scientific research services relating to infectious diseases; medical and scientific research regarding clinical trial studies on new vaccine candidates; development of pharmaceuticalspharmaceutical ingredientsvaccinesantibodies
Publications
History of USPTO decisions and trademark events.
64 publications found
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
08/11/2023
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
08/11/2023
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
08/11/2023
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
05/04/2023
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
05/04/2023
ECDR
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
05/04/2023
EWAF
TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
05/04/2023
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
05/04/2023
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
05/04/2023
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
05/04/2023
R.PR
REGISTERED-PRINCIPAL REGISTER
08/04/2020
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
05/19/2020
PUBO
PUBLISHED FOR OPPOSITION
05/19/2020
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
04/29/2020
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
04/13/2020
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
03/27/2020
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
03/27/2020
ERSI
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
03/25/2020
GNS2
NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
10/01/2019
GNSI
INQUIRY TO SUSPENSION E-MAILED
10/01/2019
CNSI
SUSPENSION INQUIRY WRITTEN
10/01/2019
GNS3
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
03/18/2019
GNSL
LETTER OF SUSPENSION E-MAILED
03/18/2019
CNSL
SUSPENSION LETTER WRITTEN
03/18/2019
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
03/18/2019
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
03/18/2019
ERSI
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
03/15/2019
GNS2
NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
09/21/2018
GNSI
INQUIRY TO SUSPENSION E-MAILED
09/21/2018
CNSI
SUSPENSION INQUIRY WRITTEN
09/21/2018
GNS3
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
03/21/2018
GNSL
LETTER OF SUSPENSION E-MAILED
03/21/2018
CNSL
SUSPENSION LETTER WRITTEN
03/21/2018
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
03/21/2018
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
03/21/2018
ERSI
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
03/20/2018
GNS2
NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
10/26/2017
GNSI
INQUIRY TO SUSPENSION E-MAILED
10/26/2017
CNSI
SUSPENSION INQUIRY WRITTEN
10/26/2017
RCCK
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
10/24/2017
GNS3
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
04/24/2017
GNSL
LETTER OF SUSPENSION E-MAILED
04/24/2017
CNSL
SUSPENSION LETTER WRITTEN
04/24/2017
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
04/12/2017
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
04/12/2017
ERSI
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
04/05/2017
GNS2
NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
11/11/2016
GNSI
INQUIRY TO SUSPENSION E-MAILED
11/11/2016
CNSI
SUSPENSION INQUIRY WRITTEN
11/11/2016
GNS3
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
05/11/2016
GNSL
LETTER OF SUSPENSION E-MAILED
05/11/2016
CNSL
SUSPENSION LETTER WRITTEN
05/11/2016
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
05/11/2016
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
05/11/2016
ALIE
ASSIGNED TO LIE
05/06/2016
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
04/22/2016
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
03/04/2016
GNRT
NON-FINAL ACTION E-MAILED
03/04/2016
CNRT
NON-FINAL ACTION WRITTEN
03/04/2016
DOCK
ASSIGNED TO EXAMINER
03/02/2016
MPMK
NOTICE OF PSEUDO MARK E-MAILED
02/26/2016
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
02/25/2016
NWAP
NEW APPLICATION ENTERED
02/23/2016
Continuous trademark protection
Get notified about every new filing that threatens M or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.